Inhibition of tumor growth and angiogenesis by vitamin D3 agents in murine renal cell carcinoma.

[1]  S. Campbell,et al.  Advances in angiogenesis research: relevance to urological oncology. , 1997, The Journal of urology.

[2]  T. Fujioka,et al.  Antitumor effects of angiogenesis inhibitor 0-(chloroacetyl-carbamoyl) fumagillol (TNP-470) against murine renal cell carcinoma. , 1996, The Journal of urology.

[3]  G. P. Studzinski,et al.  Sunlight--can it prevent as well as cause cancer? , 1995, Cancer research.

[4]  M. Yamaoka,et al.  Inhibition of tumor growth and metastasis of rodent tumors by the angiogenesis inhibitor O-(chloroacetyl-carbamoyl)fumagillol (TNP-470; AGM-1470). , 1993, Cancer research.

[5]  W Blumenfeld,et al.  Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. , 1993, The American journal of pathology.

[6]  T. Okamoto,et al.  [A study of the metabolism of vitamin D in patients with renal cell carcinoma--with special reference to serum concentration of 1 alpha, 25-(OH)2D and its clinical significance]. , 1991, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology.

[7]  L. Liotta,et al.  Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation , 1991, Cell.

[8]  J. Folkman,et al.  Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. , 1991, The New England journal of medicine.

[9]  B. Zetter,et al.  Tumor interactions with the vasculature: angiogenesis and tumor metastasis. , 1990, Biochimica et biophysica acta.

[10]  T. Katayama,et al.  Inhibition of angiogenesis by vitamin D3 analogues. , 1990, European journal of pharmacology.

[11]  K. Okada,et al.  Influence of 1 alpha-hydroxy vitamin D3 (0.25 micrograms/day) and calcium carbonate on patients with chronic renal failure at the predialytic stage. , 1989, Nihon Jinzo Gakkai shi.

[12]  A. Norman,et al.  1,25(OH)2‐Vitamin D3 receptors: gene regulation and genetic circuitry , 1988, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[13]  P. Romano,et al.  Regulation of cellular adhesion and fibronectin synthesis by 1 alpha,25-dihydroxyvitamin D3. , 1987, The Journal of biological chemistry.

[14]  J. Folkman,et al.  How is blood vessel growth regulated in normal and neoplastic tissue? G.H.A. Clowes memorial Award lecture. , 1986, Cancer research.

[15]  L. Orci,et al.  The vitamin D endocrine system: steroid metabolism, hormone receptors, and biological response (calcium binding proteins). , 1982, Endocrine reviews.

[16]  H. Sakagami,et al.  Differentiation of mouse myeloid leukemia cells induced by 1 alpha,25-dihydroxyvitamin D3. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[17]  M. Haussler,et al.  Basic and clinical concepts related to vitamin D metabolism and action (second of two parts). , 1977, The New England journal of medicine.

[18]  L. Liotta,et al.  Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. , 1974, Cancer research.

[19]  M. Haussler,et al.  1α,25-Dihydroxycholecalciferol Receptors in Intestine I. ASSOCIATION OF 1α,25-DIHYDROXYCHOLECALCIFEROL WITH INTESTINAL MUCOSA CHROMATIN , 1974 .

[20]  H. DeLuca,et al.  1α-Hydroxy Derivative of Vitamin D3: A Highly Potent Analog of 1α,25-Dihydroxyvitamin D3 , 1973, Science.

[21]  J. Folkman.  Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.

[22]  S. Manolagas,et al.  Vitamin D and the hematolymphopoietic tissue: a 1994 update. , 1994, Seminars in nephrology.